摘要
目的观察改良FOLFOX7方案对进展期胃癌患者进行新辅助化疗的临床效果及毒性反应。方法回顾性分析2005年6月至2009年1月首都医科大学附属北京友谊医院收治的30例进展期胃癌患者的临床资料。所有患者采用改良FOLFOX7方案（奥沙利铂100mg／m^2＋5-氟尿嘧啶2400rag／m^2＋甲酰四氢叶酸钙400mg／m^2）化疗2～4周期后手术治疗，并于术前和术后评估新辅助化疗的降期效果。采用χ2检验分析两种评价方法。结果30例进展期胃癌患者经改良FOLFOX7方案治疗后，27％（8／30）的患者术前分期降低，47％（14／30）的患者术后分期降低。新辅助化疗临床有效率为43％（13／30），1例患者完全缓解，化疗毒副反应轻微。手术根治切除率为93％（28／30）。术前和术后评价新辅助化疗降期效果具有一致性（χ2=2．584，P〉0．05）。结论进展期胃癌患者采用改良FOLFOX7方案进行新辅助化疗，临床有效率较高，肿瘤降期明显，耐受性良好。
Objective To investigate the efficacy and toxicity of neoadjuvant chemotherapy of modified FOLFOX7 regimen in the treatment of advanced gastric cancer. Methods The clinical data of 30 patients with advanced gastric cancer who had been adinitted to Beijing Friendship Hospital from June 2005 to January 2009 were retrospectively analyzed. All patients received modified FOLFOX7 regimen [ oxaliplatin （ 100 mg,/m2 ） ＋ fluorouracil （2400 mg/m2） ＋ calcium folinate （400 mg/m2） ] for 2-4 courses before operation. The efficacy and toxicity of the modified FOLFOX7 were evaluated before and after the operation. All data were analyzed via chi-square test. Results The pre-and postoperative downstaging rates were 27% （8/30） and 47% （ 14/30 ）, respectively. The total effective rate of modified FOLFOX7 regimen was 43% （13/30）. Complete remission was observed in 1 patient. The toxicity was mild. Radical resection was accomplished in 28 patients （93%）. There was no statistical difference between the 2 criteria in evaluating the efficacy of modified FOLFOX7 regimen （χ2 = 2. 584, P 〉 0. 05 ）. Conclusion Modified FOLFOX7 regimen is effective and well-tolerable for patients with advanced gastric cancer.
出处
《中华消化外科杂志》
CAS
CSCD
2009年第6期416-418,共3页
Chinese Journal of Digestive Surgery
关键词
胃肿瘤
新辅助化疗
FOLFOX7方案
改良
Gastric neoplasms
Neoadjuvant chemotherapy
FOLFOX7 regimen, modified
